AZAD continually invests into further development and expansion of its FP portfolios. Development and validation of FPs is undertaken at EU-based contract manufacturers facilities under the direction of Azad`s pharmaceutical and regulatory specialists to produce CTD-format Dossiers, which are then out-licensed for customers to submit marketing authorization applications worldwide (ex-USA).
|Brinzolamide + Brimonidine, 10 mg/mL + 2 mg/mL, eye drops suspension, preservative-free||Treatment of Glaucoma||Under development|
|Brinzolamide, 10 mg/ml, eye drops suspension, preservative-free||Treatment of Glaucoma||Under development|
|Ferric Carboxymaltose, 50 mg/ml, concentrate for solution for infusion||Treatment of Iron Deficiency||Under development|